Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 4/20 | 0.36 |
| ▸ | GCK | P35557 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 4/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27765633 | 0.96 | CDK8 (0.35) | CDK8GCKATMTDP1L3MBTL1 | |
| SCHEMBL3556176 | 0.86 | MAOA (0.45) | GCKATMTDP1L3MBTL1FAAH | |
| SCHEMBL27724978 | 0.85 | ATM (0.36) | CDK8GCKATMTDP1L3MBTL1 | |
| SCHEMBL3552349 | 0.82 | MET (0.40) | GCKBRAF | |
| SCHEMBL12280370 | 0.80 | CYP1A2 (0.36) | GCKATMTDP1L3MBTL1EGFR | |
| SCHEMBL28012733 | 0.79 | MAPK14 (0.37) | GCKMAPK14BRAF | |
| SCHEMBL1726338 | 0.77 | NPC1 (0.44) | MAPK14 | |
| SCHEMBL3557679 | 0.77 | KDR (0.42) | CDK8MAPK14BRAF | |
| SCHEMBL3552928 | 0.76 | MET (0.45) | MAPK14BRAF | |
| SCHEMBL3556443 | 0.76 | MET (0.47) | MAPK14BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8377938-B2 | Phenoxypyridine derivative salts and crystals thereof, and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2009142896-A3 | LANDSCAPE EDGING SYSTEM | WINK JOHN (US) | 2012-05-10 | — | — | WO | disclosed |
| CN-101198590-B | pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD | 2012-05-09 | — | — | CN | disclosed |
| EP-2062886-B1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| EP-2119706-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | Eisai R&D Management Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2062886-A1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| CN-101198590-A | Novel pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD (JP) | 2008-06-11 | — | — | CN | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | HGF, MET, FLT1 | CDK8 2308/4885GCK 726/4885ATM 4310/4885 |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | HGF, MET, MKI67 | CDK8 957/4885GCK 1217/4885ATM 2069/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | CDK8 1598/4885GCK 1018/4885ATM 3974/4885 |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | HGF, MET, HDGF | CDK8 1879/4885GCK 1068/4885ATM 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.